Search

Your search keyword '"Kos, Igor Age"' showing total 26 results
Start Over Author "Kos, Igor Age"
26 results on '"Kos, Igor Age"'

1. An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma

Author

Christofyllakis, Konstantinos, Kaddu-Mulindwa, Dominic, Lesan, Vadim, Rixecker, Torben, Kos, Igor Age, Held, Gerhard, Regitz, Evi, Pfreundschuh, Michael, Bittenbring, Joerg Thomas, Thurner, Lorenz, Poeschel, Viola, Ziepert, Marita, Altmann, Bettina, and Bewarder, Moritz

Published
2024
Full Text
View/download PDF

2. Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis

Author

Hoffmann, Marie-Christin, Fadle, Natalie, Regitz, Evi, Kos, Igor Age, Cetin, Onur, Lesan, Vadim, Preuss, Klaus-Dieter, Zaks, Marina, Stöger, Elisabeth, Zimmer, Vincent, Klemm, Philipp, Assmann, Gunter, Pfeifer, Jochen, Bittenbring, Joerg Thomas, Bewarder, Moritz, Vogt, Thomas, Pföhler, Claudia, Thurner, Bernhard, Kessel, Christoph, and Thurner, Lorenz

Published
2024
Full Text
View/download PDF

4. Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study

Author

Pfeifer, Jochen, Thurner, Bernhard, Kessel, Christoph, Fadle, Natalie, Kheiroddin, Parastoo, Regitz, Evi, Hoffmann, Marie-Christin, Kos, Igor Age, Preuss, Klaus-Dieter, Fischer, Yvan, Roemer, Klaus, Lohse, Stefan, Heyne, Kristina, Detemple, Marie-Claire, Fedlmeier, Michael, Juenger, Hendrik, Sauer, Harald, Meyer, Sascha, Rohrer, Tilman, Wittkowski, Helmut, Becker, Sören L, Masjosthusmann, Katja, Bals, Robert, Gerling, Stephan, Smola, Sigrun, Bewarder, Moritz, Birk, Einat, Keren, Andre, Böhm, Michael, Jakob, André, Abdul-Khaliq, Hashim, Anton, Jordi, Kabesch, Michael, Pino-Ramirez, Rosa Maria, Foell, Dirk, and Thurner, Lorenz

Published
2022
Full Text
View/download PDF

5. Lessons Learned from the COVID-19 Pandemic: Interpreting Vaccination Strategies in a Nationwide Demographic Study

Author

Kos, Igor Age, primary, Hajar, Faissal Nemer, additional, Sarot Pereira da Cunha, Gustavo, additional, Corte, Claudia, additional, Furlan, Luisa Augusto, additional, Santa Maria, André, additional, Valverde, Douglas, additional, Emoingt Furtado, Bárbara, additional, Morita Fernandes-Silva, Miguel, additional, and Feijó Azevedo, Valderilio, additional

Published
2024
Full Text
View/download PDF

8. B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma

Author

Thurner, Lorenz, primary, Fadle, Natalie, additional, Regitz, Evi, additional, Roth, Sophie, additional, Cetin, Onur, additional, Kos, Igor Age, additional, Hess, Simon Mauro, additional, Bein, Julia, additional, Bohle, Rainer Maria, additional, Vornanen, Martine, additional, Sundström, Christer, additional, De Leval, Laurence, additional, Tiacci, Enrico, additional, Borchmann, Peter, additional, Engert, Andreas, additional, Poeschel, Viola, additional, Held, Gerhard, additional, Schwarz, Eva C., additional, Neumann, Frank, additional, Preuss, Klaus-Dieter, additional, Hoth, Markus, additional, Küppers, Ralf, additional, Lehman, Karola, additional, Hansmann, Martin-Leo, additional, Becker, Sören L., additional, Bewarder, Moritz, additional, and Hartmann, Sylvia, additional

Published
2023
Full Text
View/download PDF

9. B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma

Author

Thurner, Lorenz, Fadle, Natalie, Regitz, Evi, Roth, Sophie, Cetin, Onur, Kos, Igor Age, Hess, Simon Mauro, Bein, Julia, Bohle, Rainer Maria, Vornanen, Martine, Sundström, Christer, de Leval, Laurence, Tiacci, Enrico, Borchmann, Peter, Engert, Andreas, Poeschel, Viola, Held, Gerhard, Schwarz, Eva C., Neumann, Frank, Preuss, Klaus -Dieter, Hoth, Markus, Kueppers, Ralf, Lehmann, Karola, Hansmann, Martin-Leo, Becker, Soeren L., Bewarder, Moritz, Hartmann, Sylvia, Thurner, Lorenz, Fadle, Natalie, Regitz, Evi, Roth, Sophie, Cetin, Onur, Kos, Igor Age, Hess, Simon Mauro, Bein, Julia, Bohle, Rainer Maria, Vornanen, Martine, Sundström, Christer, de Leval, Laurence, Tiacci, Enrico, Borchmann, Peter, Engert, Andreas, Poeschel, Viola, Held, Gerhard, Schwarz, Eva C., Neumann, Frank, Preuss, Klaus -Dieter, Hoth, Markus, Kueppers, Ralf, Lehmann, Karola, Hansmann, Martin-Leo, Becker, Soeren L., Bewarder, Moritz, and Hartmann, Sylvia

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a Hodgkin lymphoma expressing functional B-cell receptors (BCR). Recently, we described a dual stimulation model of IgD+ lymphocyte-predominant cells by Moraxella catarrhalis antigen RpoC and its superantigen MID/hag, associated with extralong CDR3 and HLA-DRB1*04 or HLA-DRB1*07 haplotype. The aim of the present study was to extend the antigen screening to further bacteria and viruses. The fragment antibody-binding (Fab) regions of seven new and 15 previously reported cases were analyzed. The reactivity of non-Moraxella spp.-reactive Fab regions against lysates of Rothia mucilaginosa was observed in 5/22 (22.7%) cases. Galactofuranosyl transferase (Gltf) and 2,3-butanediol dehydrogenase (Bdh) of R. mucilaginosa were identified by comparative silver-and immuno-staining in two-dimensional gels, with subsequent mass spectrometry and validation by western blots and enzyme-linked immunosorbent assay. Both R. mucilaginosa Gltf and Bdh induced BCR pathway activation and proliferation in vitro. Apoptosis was induced by recombinant Gltf/ETA'-immunotoxin conjugates in DEV cells expressing recombinant R. mucilaginosa-reactive BCR. Reactivity against M. catarrhalis RpoC was confirmed in 3/7 newly expressed BCR (total 10/22 reactive to Moraxella spp.), resulting in 15/22 (68.2%) cases with BCR reactivity against defined bacterial antigens. These findings strengthen the hypothesis of bacterial trigger contributing to subsets of NLPHL.

Published
2023
Full Text
View/download PDF

11. Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP

Author

Bewarder, Moritz, primary, Kaddu-Mulindwa, Dominic, additional, Kos, Igor Age, additional, Lesan, Vadim, additional, Held, Gerhard, additional, Poeschel, Viola, additional, Thurner, Lorenz, additional, Bittenbring, Joerg Thomas, additional, Schmitz, Norbert, additional, Truemper, Lorenz, additional, Pfreundschuh, Michael, additional, Christofyllakis, Konstantinos, additional, Loeffler, Markus, additional, Altmann, Bettina, additional, and Ziepert, Marita, additional

Published
2023
Full Text
View/download PDF

12. Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma

Author

Bewarder, Moritz, primary, Elbert, Michelle, additional, Christofyllakis, Konstantinos, additional, Heyne, Kristina, additional, Carbon, Gabi, additional, Fadle, Natalie, additional, Regitz, Evi, additional, Kiefer, Maximilian, additional, Kos, Igor Age, additional, Bittenbring, Joerg Thomas, additional, Neumann, Frank, additional, Fend, Falko, additional, Bonzheim, Irina, additional, and Thurner, Lorenz, additional

Published
2022
Full Text
View/download PDF

13. Adaptive humoral immune response and cellular immune status in cancer patients and patients under immunosuppression vaccinated against SARS-CoV-2

Author

Kos, Igor Age, primary, Kiefer, Maximilian, additional, Brill, Katharina, additional, Cetin, Onur, additional, Bittenbring, Joerg Thomas, additional, Ahlgrimm, Manfred, additional, Smola, Sigrun, additional, Lohse, Stefan, additional, Christofyllakis, Konstantinos, additional, Kaddu-Mulindwa, Dominic, additional, Neumann, Frank, additional, Bewarder, Moritz, additional, and Thurner, Lorenz, additional

Published
2022
Full Text
View/download PDF

15. Autoantibodies against SUMO1-DHX35 in long-COVID

Author

Thurner, Lorenz, primary, Fadle, Natalie, additional, Regitz, Evi, additional, Preuss, Klaus-Dieter, additional, Neumann, Frank, additional, Cetin, Onur, additional, Schormann, Claudia, additional, Hoffmann, Marie-Christin, additional, Herr, Christian, additional, Kheiroddin, Parastoo, additional, Rixecker, Torben Millard, additional, Bals, Robert, additional, Muller, Sylviane, additional, Thurner, Bernhard, additional, Kessel, Christoph, additional, Kabesch, Michael, additional, Bewarder, Moritz, additional, Heyne, Kristina, additional, Lensch, Christian, additional, and Kos, Igor Age, additional

Published
2022
Full Text
View/download PDF

18. Report on the Second PANLAR Review Course in Rheumatology

Author

Caballero-Uribe, Carlos Vinicius, primary, Azevedo, Valderilio Feijó, additional, Soriano, Enrique Roberto, additional, Pineda, Carlos, additional, Galarza-Maldonado, Claudio, additional, Kos, Igor Age, additional, and Jimenez, Osvaldo Castañeda, additional

Published
2018
Full Text
View/download PDF

22. Consenso brasileiro multi-institucional de pacientes sobre medicamentos biossimilares.

Author

Torres, Priscila, Kos, Igor Age, Isaac, Andreia, Oliveira, Nilma Rodrigues, da Silva, Mari Ivone, de Paula de Oliveira, Adriana, Caetano, Shaira Ferraz, Drumond, Wilton Alvarenga, Ferreira, Dayane, Peixoto, José Célio Silveira, Oliveira, Izabel, Santos, Maria Conceição dos, Kobielski, Iara Cabreiro, Silva, Abigail Gomes, de Alencar Marques, Márcia Dias, Sá, Geralda, Leitão, Julia Miguel, and Azevedo, Valderílio Feijó

Abstract

Copyright of JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde is the property of JBES: Brazilian Journal of Health Economics and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2017
Full Text
View/download PDF

23. The Experience with Biosimilars of Infliximab in Rheumatic Diseases

Author

Azevedo, Valderilio F., Kos, Igor Age, and Ariello, Leonardo

Abstract

Background: Infliximab biosimilars are the first biosimilars of monoclonal antibodies approved by the main regulatory agencies. Up to the present day, two infliximab biosimilars have been approved: CT-P13 (Celltrion), and SB2 (Biogen), but other companies have been developing candidate infliximab biosimilars that are on clinical trials: PF 06438179 (Pfizer), the ABP710 (bioCentury/Amgen) the BCD055 (JSC Biocad Russica) and BOW015 (Epirus). Methods: We have made a literature search in MedLine database using the key words [Infliximab] and [biosimilars] and [rheumatic diseases] and [rheumatisms]. We have also made a search in the clinicaltrials.org website. Conclusions: Clinical data published so far have provided important evidence on long-term efficacy and safety, immunogenicity and switching, supporting the use of CT-P13 and SB2 for the treatment of rheumatic diseases. In addition, the European experience has proved the economic advantages of the incorporation of infliximab biosimilars in clinical practice. Despite the widespread use of infliximab biosimilars there is still a lack of data regarding interchangeability between reference products and biosimilars.

Published
2017
Full Text
View/download PDF

24. Humorale und Zelluläre Immunantwort von Patienten mit COVID-19

Author

Kos, Igor Age

Abstract

Die von SARS-CoV-2 ausgelöste Erkrankung COVID-19 führte seit dem erstmaligen Auftreten in Wuhan 2019 zu einer anhaltenden Pandemie und bisher mehreren Millionen Toten. Frühzeitig gab es Hinweise auf schwere Dysregulationen des Immunsystems in Folge der Infektion. Die Pathogenese der durch SARS-CoV2 ausgelösten Komplikationen ist noch nicht vollständig geklärt. In dieser Arbeit berichten wir über die Analyse des zellulären Immunstatus, der Verhältnisse der Immunzell-Populationen zueinander, Monozyten Subpopulationen, Immunglobuline und klinische Charakteristika von Patienten mit COVID-19, die von April 2020 bis Juli 2020 auf einer Intensivstation (ICU) (N = 23) und einer Normalstation (NCU) (n = 10) behandelt wurden, im Vergleich zu zwei Kontrollgruppen: Diese bestanden ersten aus Patienten, die aus nicht-infektiösen Gründen auf der ICU behandelt wurden (n = 30) und zweiten aus Patienten, die wegen anderer Infektionen als COVID-19 auf der NCU behandelt wurden (n = 21). Patienten mit COVID-19 auf ICU wiesen im Vergleich zu den anderen Kohorten signifikante Unterschiede auf, darunter eine niedrigere Zahl an Lymphozyten, eine geringere Anzahl von CD8+ T-Zellen, einen geringeren Prozentsatz aktivierter und intermediärer Monozyten und ein erhöhtes B/T8-Zellverhältnis. Die verstorbenen Patienten mit COVID-19 auf der ICU wiesen eine geringere Anzahl von B-, T-, CD4+ T-, CD8+ T-Lymphozyten, NK-Zellen und aktivierten Monozyten auf. Das B/T8-Verhältnis zeigte sich in der Gruppe der Patienten, die COVID-19 überlebten signifikant erniedrigt. In Patienten mit COVID-19 auf ICU wurden signifikant höhere IgG1 und IgG3 Werte festgestellt, während Patienten mit COVID-19 auf NCU im Vergleich zu Patienten, die wegen anderen Infektionen als mit SARS-CoV2 auf einer NCU behandelt wurden, erhöhte Werte von IgG3 aufwies. Zusammenfassend neben vielen anderen Veränderungen des Immunsystems wurden ein erhöhtes B/T8-Zell-Verhältnis und eine geringere Anzahl aktivierter Monozyten vor allem bei Patienten mit schwerem COVID-19 beobachtet. Beide Parameter waren in Patienten mit COVID-19 auf ICU mit einem erhöhten Sterberisiko assoziiert.

Published
2022

25. Report on the Second PANLAR Review Course in Rheumatology: Biosimilars Update.

Author

Caballero-Uribe CV, Azevedo VF, Soriano ER, Pineda C, Galarza-Maldonado C, Kos IA, and Jimenez OC

Subjects
Humans, Latin America epidemiology, Societies, Medical, Biosimilar Pharmaceuticals pharmacology, Rheumatic Diseases epidemiology, Rheumatic Diseases therapy, Rheumatology methods, Rheumatology organization & administration, Rheumatology trends
Published
2020
Full Text
View/download PDF

26. The biosimilars journey: current status and ongoing challenges.

Author

Kos IA, Azevedo VF, Neto DE, and Kowalski SC

Abstract

Biosimilar products are already approved and marketed in several countries. The Food and Drug Administration has approved ten different biosimilars, and the European Medicines Agency has approved 40. Even though this scenario has provided important experience with biosimilar products, there are still challenges and unanswered questions. Up to now, a good amount of knowledge has been gathered in order to support the importance of the totality of evidence and the construction of a biosimilarity exercise for regulatory approval. In addition, the extrapolation of indications has been proved viable when a careful analysis is performed. The models for clinical trials and the use of the most sensible populations have been extensively discussed, and there is apparent homogeneity in manufacturer choices for study designs. However, some challenges remain. The lack of regulatory harmony, especially concerning naming, the marketed intended copies, the interchangeability, and the biosimilars in orphan diseases are some of those and are the focus of discussion in this review., Competing Interests: Disclosure and potential conflicts of interest: VA has received grant and speaker fees from AbbVie and Pfizer, speaker fees from UCB, Janssen, BMS, and advisory board fees from Pfizer. All the other authors have nothing to declare. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2018/09/dic.212543-COI.pdf

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results